Skip to main content
SleepCited

The Efficacy of Melatonergic Receptor Agonists Used in Clinical Practice in Insomnia Treatment: Melatonin, Tasimelteon, Ramelteon, Agomelatine, and Selected Herbs.

Kacper Żełabowski, Wojciech Pichowicz, Izabela Skowron, Jagoda Szwach, Kamil Biedka et al.
Review Molecules (Basel, Switzerland) 2025 2 인용
PubMed DOI CC-BY PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D41011705'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

연구 유형
Review
중재
The Efficacy of Melatonergic Receptor Agonists Used in Clinical Practice in Insomnia Treatment: Melatonin, Tasimelteon, Ramelteon, Agomelatine, and Selected Herbs. None
대조군
Placebo
효과 방향
Positive
비뚤림 위험
Unclear

Abstract

Insomnia is a common and complex disorder, rooted in the dysregulation of circadian rhythms, impaired neurotransmitter function, and disturbances in sleep-wake homeostasis. While conventional hypnotics such as benzodiazepines and Z-drugs are effective in the short term, their use is limited by a high potential for dependence, cognitive side effects, and withdrawal symptoms. In contrast, melatonergic receptor agonists-melatonin, ramelteon, tasimelteon, and agomelatine-represent a pharmacologically targeted alternative that modulates MT1 and MT2 receptors, which are pivotal to the regulation of circadian timing and sleep initiation. Clinical evidence supports the efficacy of these agents in reducing sleep onset latency, extending total sleep duration, and re-aligning disrupted circadian rhythms, particularly among older individuals and patients with non-24 h sleep-wake disorders. Notably, agomelatine offers additional antidepressant properties through selective antagonism of the 5-HT2C receptor in micromolar concentrations. In contrast, its agonistic activity at melatonergic receptors is observed in the low sub-nanomolar range, which illustrates the complexity of this drug's interactions with the human body. All compounds reviewed demonstrate a generally favorable safety and tolerability profile. Accumulating evidence highlights that selected medicinal plants, such as chamomilla, lemon balm, black cumin, valeriana, passionflower and lavender, may exert relevant hypnotic or anxiolytic effects, thus complementing melatonergic strategies in the management of insomnia. This structured narrative review presents a comprehensive analysis of the molecular pharmacology, receptor affinity, signaling pathways, and clinical outcomes associated with melatonergic agents. It also examines their functional interplay with serotonergic, GABAergic, dopaminergic, and orexinergic systems involved in arousal and sleep regulation. Through comparative synthesis of pharmacokinetics and neurochemical mechanisms, this work aims to inform the development of evidence-based strategies for the treatment of insomnia and circadian rhythm sleep-wake disorders.

Full Text

PDF
Loading PDF...

Figures

Tables

Table 5

CriterionMelatonergic DrugsHerbal Preparations
ExamplesMelatonin, Ramelteon, Tasimelteon, AgomelatineM. chamomilla, M. officinalis, N. sativa
Mechanism of ActionMT1/MT2 agonism, 5-HT2C antagonism (agomelatine)GABA modulation, serotonin activity, antioxidant effects
Clinical EfficacyHigh (multiple RCTs and meta-analyses)Limited (mostly pilot trials)
SafetyHigh, low abuse potentialHigh, but risk of interactions and allergies
Use in Severe InsomniaConfirmed by multiple trialsNot confirmed
CostModerate to highLow
AvailabilityPrescription only (except melatonin OTC in some regions)OTC, dietary supplements
Additional BenefitsAntidepressant effects (agomelatine)Anxiolytic, adaptogenic potential

Table 6

ICSD-3-TRThe International Classification of Sleep Disorders, Third Edition
ICD-1111th Revision of the International Classification of Diseases
DSM-55th edition of the Diagnostic and Statistical Manual of Mental Disorders
SCNSuprachiasmatic nucleus
LTPLong-term potentiation
cAMPCyclic adenosine monophosphate
ACAdenylate cyclase
PKAProtein kinase A
P-CREBPhosphorylated CREB
PKCProtein kinase C
GCGuanylyl cyclase
PLCPhospholipase C
cGMPCyclic GMP
DAGDiacylglycerol
IP3Inositol trisphosphate
PVNParaventricular nucleus
VTAVentral tegmental area
OX1R/OX2ROrexin-1-receptor/Orexin-2-receptor
GIRKG protein–regulated inward rectifier
NMDAN-methyl-D-aspartate
DMHHypothalamus
NREMNon-rapid eye movement
REMRapid eye movement
VLPOVentrolateral preoptic nucleus
TMNTuberomammillary nucleus
LCLocus coeruleus
LH/PFLateral hypothalamus/Perifornical area
GPCRG protein-coupled receptor
NQO2Quinone reductase 2
TST Total sleep time
sTSTSubjective total sleep time
SLSleep latency
sSLSubjective sleep latency
ASDAutism spectrum disorder
LPSLatency to persistent sleep
SESleep efficiency
oSOLObjective sleep onset latency
EMAEuropean Medicines Agency
MDDMajor depressive disorder
LSEQLeeds Sleep Evaluation Questionnaire
CGIClinical Global Impression
OROdds ratio
PSQIPittsburgh Sleep Quality Index
TCIMIntegrative medicines
WHOWorld Health Organization
GAD Generalized anxiety disorder
HRSDHamilton Rating Scale for Depression
GABAGamma-aminobutyric acid
NONitric oxide

References

  1. Untitled
  2. Untitled
  3. Untitled
  4. Untitled
  5. Untitled
  6. Untitled
  7. Untitled
  8. Untitled
  9. Untitled
  10. Untitled
  11. Untitled
  12. Untitled
  13. Untitled
  14. Untitled
  15. Untitled
  16. Untitled
  17. Untitled
  18. Untitled
  19. Untitled
  20. Untitled
  21. Untitled
  22. Untitled
  23. Untitled
  24. Untitled
  25. Untitled
  26. Untitled
  27. Untitled
  28. Untitled
  29. Untitled
  30. Untitled
  31. Untitled
  32. Untitled
  33. Untitled
  34. Untitled
  35. Untitled
  36. Untitled
  37. Untitled
  38. Untitled
  39. Untitled
  40. Untitled
  41. Untitled
  42. Untitled
  43. Untitled
  44. Untitled
  45. Untitled
  46. Untitled
  47. Untitled
  48. Untitled
  49. Untitled
  50. Untitled
  51. Untitled
  52. Untitled
  53. Untitled
  54. Untitled
  55. Untitled
  56. Untitled
  57. Untitled
  58. Untitled
  59. Untitled
  60. Untitled
  61. Untitled
  62. Untitled
  63. Untitled
  64. Untitled
  65. Untitled
  66. Untitled
  67. Untitled
  68. Untitled
  69. Untitled
  70. Untitled
  71. Untitled
  72. Untitled
  73. Untitled
  74. Untitled
  75. Untitled
  76. Untitled
  77. Untitled
  78. Untitled
  79. Untitled
  80. Untitled
  81. Untitled
  82. Untitled
  83. Untitled
  84. Untitled
  85. Untitled
  86. Untitled
  87. Untitled
  88. Untitled
  89. Untitled
  90. Untitled
  91. Untitled
  92. Untitled
  93. Untitled
  94. Untitled
  95. Untitled
  96. Untitled
  97. Untitled
  98. Untitled
  99. Untitled
  100. Untitled
  101. Untitled
  102. Untitled
  103. Untitled
  104. Untitled
  105. Untitled
  106. Untitled
  107. Untitled
  108. Untitled
  109. Untitled
  110. Untitled
  111. Untitled
  112. Untitled
  113. Untitled
  114. Untitled
  115. Untitled
  116. Untitled
  117. Untitled
  118. Untitled
  119. Untitled
  120. Untitled
  121. Untitled
  122. Untitled
  123. Untitled
  124. Untitled
  125. Untitled
  126. Untitled
  127. Untitled
  128. Untitled
  129. Untitled
  130. Untitled
  131. Untitled
  132. Untitled
  133. Untitled
  134. Untitled
  135. Untitled
  136. Untitled
  137. Untitled
  138. Untitled
  139. Untitled
  140. Untitled
  141. Untitled
  142. Untitled
  143. Untitled
  144. Untitled
  145. Untitled
  146. Untitled
  147. Untitled
  148. Untitled
  149. Untitled
  150. Untitled
  151. Untitled
  152. Untitled
  153. Untitled
  154. Untitled
  155. Untitled
  156. Untitled
  157. Untitled
  158. Untitled
  159. Untitled
  160. Untitled
  161. Untitled
  162. Untitled
  163. Untitled
  164. Untitled
  165. Untitled
  166. Untitled
  167. Untitled
  168. Untitled
  169. Untitled
  170. Untitled
  171. Untitled
  172. Untitled
  173. Untitled
  174. Untitled
  175. Untitled
  176. Untitled
  177. Untitled
  178. Untitled
  179. Untitled
  180. Untitled
  181. Untitled
  182. Untitled
  183. Untitled
  184. Untitled
  185. Untitled
  186. Untitled
  187. Untitled
  188. Untitled
  189. Untitled
  190. Untitled
  191. Untitled
  192. Untitled
  193. Untitled
  194. Untitled
  195. Untitled
  196. Untitled
  197. Untitled
  198. Untitled
  199. Untitled
  200. Untitled
  201. Untitled
  202. Untitled
  203. Untitled
  204. Untitled
  205. Untitled
  206. Untitled
  207. Untitled
  208. Untitled
  209. Untitled
  210. Untitled
  211. Untitled
  212. Untitled
  213. Untitled
  214. Untitled
  215. Untitled
  216. Untitled
  217. Untitled
  218. Untitled
  219. Untitled
  220. Untitled
  221. Untitled
  222. Untitled
  223. Untitled
  224. Untitled
  225. Untitled
  226. Untitled

Used In Evidence Reviews

Similar Papers